Premenstrual Syndrome Treatment Market

Premenstrual Syndrome Treatment Market Overview:

The global premenstrual syndrome treatment market size reached US$ 1,397.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,890.8 Million by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Analysis:

• Major Market Drivers: The growing demand for precision medicine, along with the rising healthcare expenditure, is positively influencing the market.
• Key Market Trends: Increasing female workforce participation and ongoing technological advancements are stimulating the growth of the market.
• Geographical Trends: North America holds the largest segment because of its strong healthcare infrastructure and robust economy, which leads to greater affordability of medications.
• Competitive Landscape: Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., SHIONOGI & Co. Ltd., among many others.
• Challenges and Opportunities: While the market faces challenges like lack of awareness and understanding about PMS, it also encounters opportunities in the development of new treatment options.
   

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group’s report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

• Analgesics
• Antidepressants
• Oral Contraceptives and Ovarian Suppression Agents
• Others
   

Analgesics accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes analgesics, antidepressants, oral contraceptives and ovarian suppression agents, and others. According to the report, analgesics represents the largest segment.

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

• Prescription
• Over-the-Counter
   

Over-the-counter holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes prescription and over-the-counter. According to the report, over-the-counter accounts for the largest market share.

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores
   

Drugs stores and retail pharmacies represent the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores and retail pharmacies, and online stores. According to the report, drugs stores and retail pharmacies represent the largest segment.

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Premenstrual Syndrome Treatment Market News:

• September 12, 2023: Vistagen, a late clinical-stage biopharmaceutical company announced positive results from exploratory phase 2A study of PH80 for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Premenstrual Syndrome Treatment Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the premenstrual syndrome treatment market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global premenstrual syndrome treatment market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the premenstrual syndrome treatment industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.